|
rs3212986
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The ERCC2-rs1799793 AA+AC > CC (OR=1.3428, 95% CI=1.0201; 1.7674) had an effect on the risk of osteosarcoma development, whereas, there were no significant associations among the other ERCC SNPs (ERCC1 rs3212986, ERCC1 rs11615, and ERCC2 rs13181) and osteosarcoma.
|
30402838 |
2018 |
|
rs12879262
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Four polymorphisms in pre-miRNAs at 14q32 miRNA cluster were associated with osteosarcoma risk in the Spanish population (rs12894467, rs61992671, rs58834075 and rs12879262).
|
30337581 |
2018 |
|
rs12894467
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Four polymorphisms in pre-miRNAs at 14q32 miRNA cluster were associated with osteosarcoma risk in the Spanish population (rs12894467, rs61992671, rs58834075 and rs12879262).
|
30337581 |
2018 |
|
rs58834075
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Four polymorphisms in pre-miRNAs at 14q32 miRNA cluster were associated with osteosarcoma risk in the Spanish population (rs12894467, rs61992671, rs58834075 and rs12879262).
|
30337581 |
2018 |
|
rs8103992
|
|
|
0.010 |
GeneticVariation |
BEFREE |
An expression quantitative trait locus for cartilage intermediate layer protein 2 (CILP2), rs8103992, was significantly associated with osteosarcoma risk after adjustment for multiple comparisons (odds ratio, 1.35; 95% CI, 1.16-1.56 [P = 7.93×10<sup>-5</sup> and P<sub>adjusted</sub> =.034]).
|
30311632 |
2018 |
|
rs145204276
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The genetic variant rs145204276 is functionally associated with the susceptibility of OS, which can function as a protective factor in the incidence of OS possibly through the regulation of GAS5.
|
30013899 |
2018 |
|
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
ERCC1 (C118T (rs11615) and C8092A (rs3212986)) and ERCC2 (A751C (rs171140) and G312A (rs1799793)) polymorphisms were analysed in 44 patients with osteosarcoma, who were treated with cisplatin based neoadjuvant chemotherapy.
|
29980176 |
2018 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
ERCC1 (C118T (rs11615) and C8092A (rs3212986)) and ERCC2 (A751C (rs171140) and G312A (rs1799793)) polymorphisms were analysed in 44 patients with osteosarcoma, who were treated with cisplatin based neoadjuvant chemotherapy.
|
29980176 |
2018 |
|
rs3212986
|
|
|
0.030 |
GeneticVariation |
BEFREE |
ERCC1 (C118T (rs11615) and C8092A (rs3212986)) and ERCC2 (A751C (rs171140) and G312A (rs1799793)) polymorphisms were analysed in 44 patients with osteosarcoma, who were treated with cisplatin based neoadjuvant chemotherapy.
|
29980176 |
2018 |
|
rs171140
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ERCC1 (C118T (rs11615) and C8092A (rs3212986)) and ERCC2 (A751C (rs171140) and G312A (rs1799793)) polymorphisms were analysed in 44 patients with osteosarcoma, who were treated with cisplatin based neoadjuvant chemotherapy.
|
29980176 |
2018 |
|
rs756340448
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ERCC1 (C118T (rs11615) and C8092A (rs3212986)) and ERCC2 (A751C (rs171140) and G312A (rs1799793)) polymorphisms were analysed in 44 patients with osteosarcoma, who were treated with cisplatin based neoadjuvant chemotherapy.
|
29980176 |
2018 |
|
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In addition, no evidence of association was observed between prognosis in osteosarcoma and <i>ERCC1</i> rs11615, <i>ERCC1</i> rs3212986, <i>ERCC1</i> rs2298881, <i>ERCC2</i> rs13181, <i>ERCC4</i> rs1800067, and <i>ERCC5</i> rs1047768 polymorphisms.
|
29950854 |
2018 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the present meta-analysis, we demonstrated that the homozygous variant genotypes in <i>ERCC2</i> rs1799793 and <i>ERCC5</i> rs2296147 were significantly associated with OS in osteosarcoma (TT vs GG for rs1799793: HR = 0.62, 95% CI = 0.41-0.93, <i>P</i><sub>heterogeneity</sub> = 0.310, <i>I</i><sup>2</sup> = 15.3%, <i>P</i> = 0.020; TT vs CC for rs2296147: HR = 0.42, 95% CI = 0.23-0.78, <i>P</i><sub>heterogeneity</sub> = 0.708, <i>I</i><sup>2</sup> = 0.0%, <i>P</i> = 0.006).
|
29950854 |
2018 |
|
rs1047768
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Here, we performed a meta-analysis to determine the strength of the association between eight polymorphisms in the <i>ERCC</i> genes (rs11615, rs3212986, rs2298881, rs13181, rs1799793, rs1800067, rs2296147, and rs1047768) and prognosis of osteosarcoma patients treated with chemotherapy.
|
29950854 |
2018 |
|
rs2296147
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our meta-analysis indicated that TT genotype in the <i>ERCC2</i> rs1799793 and <i>ERCC5</i> rs2296147 might prolong the survival time of patients with osteosarcoma, suggesting that the rs1799793 and rs2296147 polymorphisms can be used as predictors for prognosis of osteosarcoma patients treated with chemotherapy.
|
29950854 |
2018 |
|
rs3821204
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These findings suggest that the rs7025417 and rs3821204 may have a combined effect to protect against the development of OS by decreasing the expression levels of IL-33 or ST2.
|
29797504 |
2018 |
|
rs7025417
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These findings suggest that the rs7025417 and rs3821204 may have a combined effect to protect against the development of OS by decreasing the expression levels of IL-33 or ST2.
|
29797504 |
2018 |
|
rs1295925
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that rs1295925 (OR = 0.85; 95 CI = 0.76-0.94; P = 0.003) and rs3787547 (OR = 1.27; 95 CI = 1.11-1.45; P = 4.0 × 10<sup>-4</sup>) was significantly with OS susceptibility.
|
29595404 |
2018 |
|
rs3787547
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that rs1295925 (OR = 0.85; 95 CI = 0.76-0.94; P = 0.003) and rs3787547 (OR = 1.27; 95 CI = 1.11-1.45; P = 4.0 × 10<sup>-4</sup>) was significantly with OS</span> susceptibility.
|
29595404 |
2018 |
|
rs6218
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The presence of TC and CC genotypes of rs6218 indicated higher risk of osteosarcoma.
|
29232358 |
2017 |
|
rs1800470
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our subgroup analysis showed a significant association between IL-6 174G/C and IL-10 1082A/G and OS risk in Asians, while no such significant correlation was observed with TNF-α 308G/A, TNF-α 238G/A, TNF-β 252A/G and TGF-β1 29T/C polymorphisms.
|
29228633 |
2017 |
|
rs745738344
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our subgroup analysis showed a significant association between IL-6 174G/C and IL-10 1082A/G and OS risk in Asians, while no such significant correlation was observed with TNF-α 308G/A, TNF-α 238G/A, TNF-β 252A/G and TGF-β1 29T/C polymorphisms.
|
29228633 |
2017 |
|
rs747126003
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our subgroup analysis showed a significant association between IL-6 174G/C and IL-10 1082A/G and OS risk in Asians, while no such significant correlation was observed with TNF-α 308G/A, TNF-α 238G/A, TNF-β 252A/G and TGF-β1 29T/C polymorphisms.
|
29228633 |
2017 |
|
rs11615
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This suggests rs11615 may be a useful genetic marker for predicting osteosarcoma prognosis.
|
28977987 |
2017 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our meta-analysis included eleven studies in which four SNPs (ERCC1 rs11615 and rs3212986, ERCC2 rs13181 and rs1799793) reportedly associated with osteosarcoma prognosis were investigated.
|
28977987 |
2017 |